Open AccessAngiotensin converting enzymes inhibitors or angiotensin receptor blockers should be continued in COVID-19 patients with hypertension
Author(s) -
Cuimeng Tian,
Nan Li,
Yi Bai,
Han Xiao,
Shu Li,
Qi Ge,
Ning Shen,
Qingbian Ma
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i1.47
Subject(s) - medicine , angiotensin receptor blockers , angiotensin converting enzyme , angiotensin ii , covid-19 , renin–angiotensin system , angiotensin converting enzyme 2 , angiotensin 1 , pharmacology , angiotensin receptor , angiotensin ii receptor type 1 , receptor , blood pressure , disease , infectious disease (medical specialty)
Recent studies have revealed that sustained ingestion of angiotensin converting enzymes inhibitors or angiotensin receptor blockers (ACEIs/ARBs) had no harmful effects on coronavirus disease 2019 (COVID-19) patients complicated with hypertension.